Fukumoto S - Search Results

1

Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.

Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama JJ, Fukagawa M, Noguchi S. Yamashita H, et al. Among authors: fukumoto s. Endocr J. 2007 Jun;54(3):465-70. doi: 10.1507/endocrj.k06-156. Epub 2007 Apr 27. Endocr J. 2007. PMID: 17464094 Free article.

2

Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma.

Fukumoto S, Matsumoto T, Ikeda K, Yamashita T, Watanabe T, Yamaguchi K, Kiyokawa T, Takatsuki K, Shibuya N, Ogata E. Fukumoto S, et al. Arch Intern Med. 1988 Apr;148(4):921-5. Arch Intern Med. 1988. PMID: 2895617

3

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Shimada T, et al. Among authors: fukumoto s. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6500-5. doi: 10.1073/pnas.101545198. Epub 2001 May 8. Proc Natl Acad Sci U S A. 2001. PMID: 11344269 Free PMC article.

4

Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia.

Fukumoto S, Yamashita T. Fukumoto S, et al. Endocr J. 2001 Dec;48(6):603-10. doi: 10.1507/endocrj.48.603. Endocr J. 2001. PMID: 11873859 Free article. Review. No abstract available.

5

Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.

Fukumoto S, Yamashita T. Fukumoto S, et al. Curr Opin Nephrol Hypertens. 2002 Jul;11(4):385-9. doi: 10.1097/00041552-200207000-00003. Curr Opin Nephrol Hypertens. 2002. PMID: 12105387 Review.

6

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Shimada T, et al. Among authors: fukumoto s. Endocrinology. 2002 Aug;143(8):3179-82. doi: 10.1210/endo.143.8.8795. Endocrinology. 2002. PMID: 12130585

7

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. Yamazaki Y, et al. Among authors: fukumoto s. J Clin Endocrinol Metab. 2002 Nov;87(11):4957-60. doi: 10.1210/jc.2002-021105. J Clin Endocrinol Metab. 2002. PMID: 12414858

8

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Fukumoto S, Yamashita T. Fukumoto S, et al. N Engl J Med. 2003 Jul 31;349(5):505-6; author reply 505-6. N Engl J Med. 2003. PMID: 12892105 No abstract available.

9

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Shimada T, et al. Among authors: fukumoto s. Biochem Biophys Res Commun. 2004 Feb 6;314(2):409-14. doi: 10.1016/j.bbrc.2003.12.102. Biochem Biophys Res Commun. 2004. PMID: 14733920

10

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Shimada T, et al. Among authors: fukumoto s. J Clin Invest. 2004 Feb;113(4):561-8. doi: 10.1172/JCI19081. J Clin Invest. 2004. PMID: 14966565 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

939 results

Search Page

Filters